HOME ·

CSPC Pharmaceutical Group

CSPC Pharmaceutical Group (01093.HK): Receives US$30 Million Upfront Payment Under siRNA Collaboration Agreement with AstraZeneca
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-12
CSPC Pharmaceutical Group (01093.HK): Phase I Clinical Trial of SYS6063 for Relapsed and Refractory Systemic Lupus Erythematosus Initiated at First Study Site in China
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-11
CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-10
CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-16
CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-14
CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-01
CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA
Tags：
CSPC Pharmaceutical Group01093.HK
2026-06-18
CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted
Tags：
CSPC Pharmaceutical Group01093.HK
2026-06-16
CSPC Pharmaceutical Group (01093.HK): Albumin-bound Paclitaxel for Injection (II) Approved for Marketing
Tags：
CSPC Pharmaceutical Group01093.HK
2026-06-15